Table 2.
Cost-effectiveness of the introduction of MCADD newborn screening in France
| Description of results | Introduction of MCADD screening | Introduction of MCADD screening combined with switch to MS/MS for PKU screening* |
|---|---|---|
|
Effectiveness | ||
| Deaths averted |
5.47 |
5.47 |
| Mild neurological sequelae prevented |
1.37 |
1.37 |
| Severe neurological sequelae prevented |
1.37 |
1.37 |
| LY gained |
128 |
128 |
| QALY gained |
138 |
138 |
|
Costs | ||
| Costs of testing alone† (€) |
3 187 660 |
1 742 702 |
| Net incremental costs of screening ‡(€) |
2 493 055 |
1 048 097 |
|
Incremental cost-effectiveness ratios | ||
| € per LY gained |
19 478 |
8 189 |
| € per QALY gained | 18 033 | 7 581 |
* The cost of the current technology PKU screening test (€1.76) was subtracted from that of the MS/MS screening test. The incremental effectiveness was the same as that for the introduction of MCADD screening alone as it was assumed that the performance of MS/MS for PKU screening was similar to that of the current technology; see text.
† Includes the cost of screening and confirmation tests.
‡ Includes the cost of testing as well as the cost of follow-up and of management of diagnosed patients.